Glucagon-like peptide-1 receptor agonists mitigate the risk of major adverse cardiovascular events in patients with atopic dermatitis and type 2 diabetes

Supplementary materials for a study examining the impact of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on cardiovascular outcomes in patients with atopic dermatitis.